WALTHAM, Mass.— Scipher Medicine has announced a new partnership with Kythera Labs aimed at accelerating the development of precision treatments for autoimmune diseases by integrating advanced data capabilities.
The collaboration brings together Scipher’s real-world clinical and genomic insights—generated through its PrismRA® test—with Kythera’s enriched multi-source electronic health records (EHR) and claims data. The companies say the integration will unlock new opportunities for personalized diagnostics and treatment strategies in rheumatology.
“This strategic partnership unites the strength of precision medicine with real-world data to accelerate the development and delivery of transformative therapies,” said Reg Seeto, CEO of Scipher Medicine. “By combining Scipher’s unique and industry-leading clinico-transcriptomic rheumatology data assets with Kythera’s data-transforming technology, we can take fuller advantage of novel data and advance personalized medicine to improve patient lives.”
Kythera’s data platform leverages proprietary patient mastering algorithms that maintain patient privacy while delivering high-fidelity matches—achieving a 98% match rate to Scipher’s datasets. This capability allows for the synthesis of diverse real-world data streams, providing a more comprehensive view of disease-specific therapeutic areas.
Jeff McDonald, CEO and Co-Founder of Kythera Labs, emphasized the impact of the integration: “By connecting the depth of Scipher’s molecular biobank data with our real-world data, we can build a bench-to-bedside bridge that will assist Scipher to uncover deeper insights and advance the development of new therapies for patients.”
The partnership is expected to fuel discoveries in autoimmune disease research and bolster the use of real-world evidence to guide treatment decisions.
